newsfilter
← Latest News
GlobeNewswire·

Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that